Study of RAS(ON) Inhibitors in Patients with Gastrointestinal Solid Tumors

Launched by REVOLUTION MEDICINES, INC. · May 30, 2024

Keywords

ClinConnect Summary

This clinical trial is studying a new type of treatment called RAS(ON) inhibitors for patients with certain types of gastrointestinal cancers, specifically colorectal cancer and pancreatic cancer. The goal is to find out how safe these new drugs are, how well they work, and how they can be combined with standard treatments that patients are already receiving. The study is currently looking for participants who are at least 18 years old and have specific types of cancer that are not easily treatable or have spread to other parts of the body.

To be eligible for the trial, participants should be in relatively good health, with sufficient organ function, and have a confirmed diagnosis of the cancers mentioned. Those with certain conditions, like primary brain tumors or significant gastrointestinal issues, may not qualify. If chosen to participate, patients will receive the new treatment alongside established therapies and will be closely monitored for any side effects and how their cancer responds. This trial is an important step in exploring new options for patients facing challenging cancer diagnoses.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• All Patients (unless otherwise noted):
• • ≥ 18 years of age
• • ECOG PS is 0 to 1
• • Adequate organ function as outlined by the study
• • Pathologically or cytologically documented pancreatic carcinoma or poorly differentiated pancreatic carcinoma with metastatic disease or RAS-mutated, histologically or cytologically confirmed colorectal adenocarcinoma with documented unresectable or metastatic disease (Subprotocol A, B, and C)
• • Presence of RAS G12D mutation (Subprotocol D, E, F)
• Exclusion Criteria:
• All Patients:
• • Primary central nervous system (CNS) tumors
• • Impaired gastrointestinal (GI) function that may significantly alter the absorption of RMC drugs
• • Major surgery within 28 days of first dose
• • Other inclusion/exclusion criteria may apply.

Trial Officials